At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,456 enrolled
Drug / intervention
Dapivirine Vaginal Ringcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
International Partnership for Microbicides, Inc.·interventional·Posted Aug 8, 2016·Updated Oct 25, 2022
In Brief
A Phase 3 clinical trial evaluating Dapivirine Vaginal Ring for Human Immunodeficiency Virus. Completed, enrolled 1,456 participants across 17 sites in 4 countries.
Detailed Summary
HIV Open-label Prevention Extension (HOPE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesMalawi, South Africa, Uganda, Zimbabwe
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedAug 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedAug 8, 2016
Enrollment StartJul 18, 2016
Primary CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.9 years ago
Interventions
Dapivirine Vaginal Ringcombination
Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.